Verrica Q4 2023 YCANTH revenue $1.9M; net loss $24.6M vs $5.9M prior year

Verrica Pharmaceuticals Inc.

2023-FY EPS reported -$1.48 revenue$5,124,000

Full-year 2023 YCANTH product revenue $4.7M; first commercial revenue after Q3 2023 launch.
Net loss FY 2023 $67.0M ($1.48 per share) vs $24.5M ($0.72 per share) in FY 2022; non-GAAP net loss $51.8M ($1.14 per share).
SG&A expenses surged to $47.3M for FY 2023 (FY 2022: $17.4M) driven by commercial ramp and stock compensation.
Cash and equivalents $69.5M as of Dec 31, 2023; runway into Q2 2025.
CMS issued permanent J-code for YCANTH (effective Apr 1, 2024); FDA aligned on Phase 3 design for common warts; VP-315 Phase 2 top-line data expected H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Verrica Pharmaceuticals Inc. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 29, 2024, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-051876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.